Skip to content
Catalyst

synephrineWhat was measured

Measured, with no finding

387 endpoints

Show what was measuredHide what was measured
  • duration of medication administration

    no effect

    Results showed no statistically significant differences across all aroma conditions for either resistive behavior or duration of administration

    PMID 12083347 · one of two readings recorded this

  • resistive behavior and duration of administration

    no effect

    Also, there were no statistically significant differences based on gender

    PMID 12083347 · one of two readings recorded this

  • resistive behavior during medication administration

    no effect

    Results showed no statistically significant differences across all aroma conditions for either resistive behavior or duration of administration

    PMID 12083347 · one of two readings recorded this

  • weight loss

    no effect, n = 20

    identified only 1 eligible randomized placebo controlled trial, which followed 20 patients for 6 weeks, demonstrated no statistically significant benefit for weight loss

    PMID 15541270 · one of two readings recorded this

  • blood pressure

    no effect

    Blood pressures for the hypertensive individuals did not change significantly in response to the dietary supplement

    PMID 21448304 · one of two readings recorded this

  • dependent variables

    no effect

    No significant differences were observed for the dependent variables in the female group

    PMID 21448304 · one of two readings recorded this

  • dependent variables

    no effect

    males did not demonstrate significant differences when the dietary supplement was ingested

    PMID 21448304 · one of two readings recorded this

  • effect sizes of gender and caffeine-consumption subgroup analyses

    The effects based on number of subjects per group were all below 0.4, indicating low to moderate influence

    PMID 21448304 · one of two readings recorded this

  • heart rate and blood pressure

    no effect

    As with the previous analyses, no significant differences were observed for heart rates or blood pressures between the experimental and placebo control groups

    PMID 21448304 · one of two readings recorded this

  • heart rate, blood pressure and metabolic variables

    no effect, n = 23

    No statistical differences were observed within groups or between groups for any of the measures

    PMID 21448304 · one of two readings recorded this

  • respiratory exchange ratio (RER)

    decreases

    there was a small but significant change in RER data for the low caffeine users relative to both the placebo control group and the pre-treatment baseline for the low caffeine group

    PMID 21448304 · one of two readings recorded this

  • respiratory exchange ratio (RER)

    decreases

    After ingestion of dietary supplement the low caffeine users exhibited a decrease in RER from 0.84 ± 0.05 to 0.81 ± 0.04

    PMID 21448304 · one of two readings recorded this

  • resting heart rate, auscultatory blood pressure and respiratory exchange ratio after the supplement versus placebo

    no effect, no statistical differences within or between groups for any measure, n = 23

    Not recorded as a finding: the intervention held more than the compound

    No statistical differences were observed within groups or between groups for any of the measures.

    PMID 21448304 · one of two readings recorded this

  • resting heart rate, systolic and diastolic blood pressure, mean arterial pressure and respiratory exchange ratio after a multi-ingredient capsule

    no effect

    Not recorded as a finding: the intervention held more than the compound

    No statistical differences were observed within groups or between groups for any of the measures.

    PMID 21448304 · one of two readings recorded this

  • baseline diastolic blood pressure

    The average baseline blood pressures and resting heart-rates for the study cohort were well within the normal ranges of 121/74 mm Hg and 70 BPM

    PMID 21537493 · one of two readings recorded this

  • baseline-ending change in blood pressure and heart rate, between-group differences

    no effect

    None of the baseline-ending changes approached statistical significance nor were there any statistically significant differences between any of the five study groups

    PMID 21537493 · one of two readings recorded this

  • baseline resting heart rate

    The average baseline blood pressures and resting heart-rates for the study cohort were well within the normal ranges of 121/74 mm Hg and 70 BPM

    PMID 21537493 · one of two readings recorded this

  • baseline systolic blood pressure

    The average baseline blood pressures and resting heart-rates for the study cohort were well within the normal ranges of 121/74 mm Hg and 70 BPM

    PMID 21537493 · one of two readings recorded this

  • change in resting metabolic rate (kcal) 75 min after ingestion, MedGem hand-held indirect calorimeter; also seated blood pressure, heart rate and 10-item self-report symptoms

    increases, 65 kcals over placebo for 50 mg p-synephrine alone (Group 2), n = 10

    Not recorded as a finding: this platform holds no node for the endpoint

    As compared to placebo, 50 mg p-synephrine (Advantra Z®) alone (Group 2) more than doubled consumption by 65 kcals over placebo.

    PMID 21537493 · one of two readings recorded this

  • resting metabolic rate by MedGem hand-held indirect calorimeter 75 min after p-synephrine 50 mg (as Advantra Z) alone versus placebo; blood pressure and heart rate were also measured

    RMR change 65 kcal greater than placebo, no test against placebo stated for this group

    Not recorded as a finding: this platform holds no node for the endpoint

    As compared to placebo, 50 mg p-synephrine (Advantra Z®) alone (Group 2) more than doubled consumption by 65 kcals over placebo.

    PMID 21537493 · one of two readings recorded this

  • resting metabolic rate by MedGem hand-held indirect calorimeter (oxygen consumption only), seated, change from baseline in kcal at 75 min after an oral dose; also blood pressure, heart rate and a 10-item self-report symptom scale

    increases, 65 kcal greater than placebo (Group 2, 50 mg p-synephrine alone); no significance stated for this contrast

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    As compared to placebo, 50 mg p-synephrine (Advantra Z®) alone (Group 2) more than doubled consumption by 65 kcals over placebo.

    PMID 21537493 · one of two readings recorded this

  • resting metabolic rate, change from baseline in kcal at 75 min after ingestion, measured seated with the MedGem hand-held indirect calorimeter (oxygen consumption only), p-synephrine 50 mg as Advantra Z alone vs V-8 juice placebo

    increases, 65 kcal over placebo for the p-synephrine-alone group; no test statistic stated for that contrast, n = 10

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    As compared to placebo, 50 mg p-synephrine (Advantra Z®) alone (Group 2) more than doubled consumption by 65 kcals over placebo.

    PMID 21537493 · one of two readings recorded this

  • resting metabolic rate change from baseline

    increases, n = 10

    As compared to placebo, 50 mg p-synephrine (Advantra Z®) alone (Group 2) more than doubled consumption by 65 kcals over placebo

    PMID 21537493 · one of two readings recorded this

  • resting metabolic rate change from baseline

    increases, n = 10

    In Group 3, adding 600 mg naringin to the 50 mg p-synephrine further increased calorie consumption more than three-fold to 122 kcals over placebo

    PMID 21537493 · one of two readings recorded this

  • resting metabolic rate change from baseline

    increases, n = 10

    The addition of 100 mg hesperidin to the p-synephrine plus naringin in Group 4 resulted in a further increase in calorie consumption by 5-fold to 183 kcal over placebo

    PMID 21537493 · one of two readings recorded this

  • resting metabolic rate change from baseline

    increases, n = 10

    However, in Group 5, when the amount of hesperidin consumed in conjunction with the 50 mg p-synephrine plus 600 mg naringin was increased to 1000 mg, the increase in calorie consumption over placebo was only 79 kcal

    PMID 21537493 · one of two readings recorded this

  • resting metabolic rate change from baseline

    increases, p = 0.001, n = 10

    a repeated-measures Students' t-test revealed that the changes from baseline in Group 3 and Group 4 were both statistically significant (P=0.001 and 0.030, respectively)

    PMID 21537493 · one of two readings recorded this

  • resting metabolic rate change from baseline

    increases, p = 0.03, n = 10

    a repeated-measures Students' t-test revealed that the changes from baseline in Group 3 and Group 4 were both statistically significant (P=0.001 and 0.030, respectively)

    PMID 21537493 · one of two readings recorded this

  • resting metabolic rate increase, significance test against placebo

    increases, p = 0.039, n = 10

    the increases in RMR in Group 4 was significantly greater than placebo (P=0.039)

    PMID 21537493 · one of two readings recorded this

  • systolic and diastolic blood pressure and heart rate change

    no effect

    At the conclusion of the study (75 min.), no increases in either systolic or diastolic blood pressures or heart rate were observed

    PMID 21537493 · one of two readings recorded this

  • ten self-reported symptom ratings

    no effect

    As compared to the placebo group, none of the changes in these 10 self-reported symptoms were statistically significant either 45 or 75 min. from baseline

    PMID 21537493 · one of two readings recorded this

  • ten self-reported symptom ratings

    no effect

    As compared to the placebo group, none of the changes in these 10 self-reported symptoms were statistically significant either 45 or 75 min. from baseline

    PMID 21537493 · one of two readings recorded this

  • Cure-markedly effective cases, cumulative at interim analysis 1

    n = 62

    1 | 32 | 30 | 20 | 12 | 14 | 16 | 2.45 | 3.83

    PMID 21762493 · one of two readings recorded this

  • Cure-markedly effective cases, cumulative at interim analysis 2

    n = 116

    2 | 60 | 56 | 38 | 22 | 26 | 30 | 4.89 | 7.16

    PMID 21762493 · one of two readings recorded this

  • Cure-markedly effective cases, cumulative at interim analysis 3

    n = 160

    3 | 82 | 78 | 55 | 27 | 35 | 43 | 8.89 | 9.82

    PMID 21762493 · one of two readings recorded this

  • Cure-markedly effective rate, odds ratio for IFCA relative to IFCS

    increases, n = 160

    the median unbiased estimate of the odds ratio (OR) for the benefit of IFCA relative to IFCS was 2.91 with 95%CI: 1.40 to 6.06

    PMID 21762493 · one of two readings recorded this

  • Cure-markedly effective rate (primary outcome), at stopping

    increases, p = 0.0036, n = 160

    the cure-markedly effective rates were 67% for IFCA group and 45% for IFCS group, the one-sided p-value was 0.0036

    PMID 21762493 · one of two readings recorded this

  • Syndrome integral, after treatment

    n = 160

    the after-treatment syndrome integral were 5.5 ± 2.1 for IFCA group and 6.3 ± 2.3 for IFCS group

    PMID 21762493 · one of two readings recorded this

  • Syndrome integral, before treatment

    no effect, n = 160

    Before-treatment syndrome integral | 17.3 ± 4.8 | 17.0 ± 4.3

    PMID 21762493 · one of two readings recorded this

  • Average concentric force across successive sets, time effect

    decreases, p = 0.03, n = 12

    A significant time effect was observed [P = 0.03] where average concentric force decreased from set 1 through set 6 at various points (data not shown)

    PMID 26388707 · one of two readings recorded this

  • Average power across successive sets, time effect

    decreases, p = 0.0001, n = 12

    A significant time effect was observed [P < 0.0001] where average power decreased with each successive set

    PMID 26388707 · one of two readings recorded this

  • Average power, mean of 6 sets, S vs CT and P

    no effect, n = 12

    Although mean power during S was higher than CT and P, this value did not reach statistical significance

    PMID 26388707 · one of two readings recorded this

  • Average power, mean of 6 sets, SCF vs CT and P

    increases, p = 0.03, n = 12

    The mean power for all 6 sets was significantly higher in SCF compared to CT and P by ~6.2 ± 8.0 % [P = 0.03]

    PMID 26388707 · one of two readings recorded this

  • Average power, mean of 6 sets

    increases, n = 12

    Mean | 697 ± 108.6 | 697 ± 106.5 | 718.8 ± 124.6 | 743.0 ± 129.3*

    PMID 26388707 · one of two readings recorded this

  • Average power, set 1

    n = 12

    Set 1 | 827.7 ± 160.8 | 870.4 ± 153.9 | 860.8 ± 155.0 | 875.6 ± 160.4

    PMID 26388707 · one of two readings recorded this

  • Average power, set 2

    n = 12

    Set 2 | 734.3 ± 127.2a | 756.7 ± 144.3a | 777.5 ± 160.9a | 794.4 ± 152.5a

    PMID 26388707 · one of two readings recorded this

  • Average power, set 3

    n = 12

    Set 3 | 681.2 ± 126.6ab | 677.1 ± 119.2ab | 703.6 ± 186.4ab | 729.7 ± 150.5ab

    PMID 26388707 · one of two readings recorded this

  • Average power, set 4

    n = 12

    Set 4 | 653.1 ± 134.1ab | 622.6 ± 133.7abc | 642.8 ± 169.4abc | 682.4 ± 144.6abc

    PMID 26388707 · one of two readings recorded this

  • Average power, set 5

    n = 12

    Set 5 | 600.9 ± 113.8abcd | 598.2 ± 131.2abc | 622.8 ± 140.2abc | 644.7 ± 153.0abcd

    PMID 26388707 · one of two readings recorded this

  • Average power, set 6

    n = 12

    Set 6 | 595.1 ± 100.5abcd | 574.4 ± 114.6abcde | 561.4 ± 121.4abcde | 614.8 ± 141.8abcde

    PMID 26388707 · one of two readings recorded this

  • Average velocity across successive sets, time effect

    decreases, p = 0.0001, n = 12

    A significant time effect was observed [P < 0.0001] where average velocity decreased with each successive set

    PMID 26388707 · one of two readings recorded this

  • Average velocity, mean of 6 sets, S vs CT and P

    no effect, n = 12

    Although mean velocity during S was higher than CT and P, this value did not reach statistical significance

    PMID 26388707 · one of two readings recorded this

  • Average velocity, mean of 6 sets

    increases, n = 12

    Mean | 0.38 ± 0.05 | 0.38 ± 0.06 | 0.39 ± 0.07 | 0.40 ± 0.07*

    PMID 26388707 · one of two readings recorded this

  • Average velocity per set, SCF vs CT and P

    increases, p = 0.04, n = 12

    The mean velocity per set was significantly greater [P = 0.04] in SCF than CT and P by ~6.5 ± 8.0 %

    PMID 26388707 · one of two readings recorded this

  • Average velocity, set 1

    n = 12

    Set 1 | 0.46 ± 0.06 | 0.49 ± 0.06 | 0.47 ± 0.06 | 0.48 ± 0.05

    PMID 26388707 · one of two readings recorded this

  • Average velocity, set 2

    n = 12

    Set 2 | 0.41 ± 0.05a | 0.42 ± 0.07a | 0.43 ± 0.07a | 0.44 ± 0.07a

    PMID 26388707 · one of two readings recorded this

  • Average velocity, set 3

    n = 12

    Set 3 | 0.38 ± 0.06ab | 0.38 ± 0.07ab | 0.38 ± 0.09ab | 0.40 ± 0.07ab

    PMID 26388707 · one of two readings recorded this

  • Average velocity, set 4

    n = 12

    Set 4 | 0.36 ± 0.06ab | 0.34 ± 0.07abc | 0.35 ± 0.09abc | 0.38 ± 0.08abc

    PMID 26388707 · one of two readings recorded this

  • Average velocity, set 5

    n = 12

    Set 5 | 0.33 ± 0.06abcd | 0.33 ± 0.08abc | 0.34 ± 0.07abc | 0.35 ± 0.08abcd

    PMID 26388707 · one of two readings recorded this

  • Average velocity, set 6

    n = 12

    Set 6 | 0.33 ± 0.06abcd | 0.32 ± 0.07abcde | 0.31 ± 0.07abcde | 0.34 ± 0.08abcde

    PMID 26388707 · one of two readings recorded this

  • Blood lactate across sampling times, time effect

    increases, p = 0.0001, n = 12

    A significant time effect was observed [P < 0.0001] where blood lactate was significantly elevated at T3, T4, and T5 compared to T1 and T2

    PMID 26388707 · one of two readings recorded this

  • Blood lactate, supplement effect

    no effect, p = 0.98, n = 12

    No significant supplement effects were observed [P = 0.98]

    PMID 26388707 · one of two readings recorded this

  • Body mass during each experimental protocol

    no effect, n = 12

    Body mass did not significantly differ during each experimental protocol; CT = 82.0 ± 9.2 kg; P = 81.7 ± 9.4 kg; S = 82.0 ± 9.8 kg; and SCF = 81.6 ± 9.4 kg

    PMID 26388707 · one of two readings recorded this

  • Daily dietary energy intake

    n = 12

    Subjects consumed an average of 2,594.2 ± 568.3 kcals per day

    PMID 26388707 · one of two readings recorded this

  • Mean concentric force of 6 sets

    no effect, p = 0.24, n = 12

    The mean concentric force across all 6 sets did not significantly differ among conditions (CT = 1875.9 ± 229.6 N; P = 1901.1 ± 210.5 N; S = 1898.1 ± 217.0 N; SCF = 1902.7 ± 222.9 N) [P = 0.24]

    PMID 26388707 · one of two readings recorded this

  • Mean peak power of 6 sets

    no effect, p = 0.67, n = 12

    No significant differences were observed [P = 0.67] between treatments when examining the mean peak powers of all 6 sets (CT = 1315.2 ± 195.9 W; P = 1289.8 ± 170.6 W; S = 1294.0 ± 174.4 W; SCF = 1329.1 ± 197.2 W)

    PMID 26388707 · one of two readings recorded this

  • Mean peak velocity of 6 sets

    no effect, p = 0.84, n = 12

    No significant differences were observed [P = 0.84] between treatments when examining the mean peak velocities of all 6 sets (CT = 0.71 ± 0.06 m⋅s−1; P = 0.70 ± 0.10 m⋅s−1; S = 0.70 ± 0.07 m⋅s−1; SCF = 0.72 ± 0.08 m⋅s−1)

    PMID 26388707 · one of two readings recorded this

  • Mean session RPE, treatment effect

    no effect, p = 0.18, n = 12

    no significant treatments effects were observed for the mean session RPE [P = 0.18]

    PMID 26388707 · one of two readings recorded this

  • Nutritional intake across experimental conditions

    no effect, n = 12

    Statistical analysis of the 3-day dietary records showed that subject nutritional intake did not vary between the four experimental conditions

    PMID 26388707 · one of two readings recorded this

  • Peak concentric force, mean of 6 sets, treatment effect

    no effect, p = 0.21, n = 12

    No significant differences were observed [P = 0.21] between treatments when examining the mean peak concentric force of all 6 sets

    PMID 26388707 · one of two readings recorded this

  • Peak concentric force, mean of 6 sets

    no effect, n = 12

    Mean | 2212.1 ± 258.0 | 2235.0 ± 266.7 | 2248.8 ± 266.9 | 2268.5 ± 277.1

    PMID 26388707 · one of two readings recorded this

  • Peak concentric force, set 1

    n = 12

    Set 1 | 2256.5 ± 290.3 | 2295.1 ± 281.6 | 2287.8 ± 286.2 | 2328.8 ± 306.5

    PMID 26388707 · one of two readings recorded this

  • Peak concentric force, set 2

    n = 12

    Set 2 | 2232.6 ± 276.9 | 2262.0 ± 296.4a | 2265.9 ± 283.2 | 2301.0 ± 289.7

    PMID 26388707 · one of two readings recorded this

  • Peak concentric force, set 3

    n = 12

    Set 3 | 2217.4 ± 249.5 | 2249.4 ± 272.0a | 2252.7 ± 259.0a | 2277.1 ± 283.6ab

    PMID 26388707 · one of two readings recorded this

  • Peak concentric force, set 4

    n = 12

    Set 4 | 2207.0 ± 254.8a | 2224.5 ± 270.8a | 2251.9 ± 280.7a | 2262.0 ± 287.0ab

    PMID 26388707 · one of two readings recorded this

  • Peak concentric force, set 5

    n = 12

    Set 5 | 2184.1 ± 258.4ab | 2208.4 ± 251.9abc | 2224.9 ± 267.8ab | 2227.5 ± 268.6abcd

    PMID 26388707 · one of two readings recorded this

  • Peak concentric force, set 6

    n = 12

    Set 6 | 2175.3 ± 252.9ab | 2170.9 ± 240.4abcde | 2209.7 ± 244.0abc | 2214.3 ± 241.6abcd

    PMID 26388707 · one of two readings recorded this

  • Peak power across successive sets, time effect

    decreases, p = 0.0001, n = 12

    A significant time effect was observed [P < 0.0001] where peak powers decreased with each successive set (data not shown)

    PMID 26388707 · one of two readings recorded this

  • Peak velocity across successive sets, time effect

    decreases, p = 0.0001, n = 12

    A significant time effect was observed [P < 0.0001] where peak velocities decreased with each successive set (data not shown)

    PMID 26388707 · one of two readings recorded this

  • Rating of perceived exertion, session mean

    n = 12

    Mean | 7.23 ± 1.12 | 7.14 ± 1.58 | 6.84 ± 1.49 | 7.06 ± 1.44

    PMID 26388707 · one of two readings recorded this

  • Rating of perceived exertion, set 1

    n = 12

    Set 1 | 5.36 ± 1.5 | 5.18 ± 1.60 | 5.14 ± 1.27 | 5.41 ± 1.46

    PMID 26388707 · one of two readings recorded this

  • Rating of perceived exertion, set 2

    n = 12

    Set 2 | 6.55 ± 1.6a | 6.55 ± 2.02a | 6.23 ± 1.57a | 6.36 ± 1.63a

    PMID 26388707 · one of two readings recorded this

  • Rating of perceived exertion, set 3

    n = 12

    Set 3 | 7.14 ± 1.10ab | 7.05 ± 1.98ab | 6.73 ± 1.79ab | 7.00 ± 1.84ab

    PMID 26388707 · one of two readings recorded this

  • Rating of perceived exertion, set 4

    n = 12

    Set 4 | 7.55 ± 1.29abc | 7.59 ± 1.71abc | 7.18 ± 1.94abc | 7.50 ± 1.72abc

    PMID 26388707 · one of two readings recorded this

  • Rating of perceived exertion, set 5

    n = 12

    Set 5 | 7.91 ± 1.22abc | 7.91 ± 1.51abc | 7.50 ± 1.66abc | 7.73 ± 1.68abc

    PMID 26388707 · one of two readings recorded this

  • Rating of perceived exertion, set 6

    n = 12

    Set 6 | 8.91 ± 1.22abcde | 8.55 ± 1.37abcde | 8.27 ± 1.49abcde | 8.36 ± 1.36abcde

    PMID 26388707 · one of two readings recorded this

  • Repetition number per set, supplement effect

    no effect, n = 12

    No supplement effect was observed when analyzing repetition number per set

    PMID 26388707 · one of two readings recorded this

  • Repetition performance across successive sets

    decreases, p = 0.0001, n = 12

    A significant main effect was observed [P < 0.0001] where repetition performance decreased with each successive set during all treatments

    PMID 26388707 · one of two readings recorded this

  • Repetitions completed, set 1

    n = 12

    Set 1 | 10.0 ± 0.0 | 10.0 ± 0.0 | 10.0 ± 0.0 | 10.0 ± 0.0

    PMID 26388707 · one of two readings recorded this

  • Repetitions completed, set 2

    n = 12

    Set 2 | 8.1 ± 2.3a | 9.2 ± 1.1 | 9.3 ± 1.2 | 8.9 ± 1.7

    PMID 26388707 · one of two readings recorded this

  • Repetitions completed, set 3

    n = 12

    Set 3 | 6.6 ± 2.5ab | 6.7 ± 3.0ab | 7.8 ± 3.2ab | 7.7 ± 2.3ab

    PMID 26388707 · one of two readings recorded this

  • Repetitions completed, set 4

    n = 12

    Set 4 | 6.0 ± 2.7abc | 5.9 ± 3.1ab | 6.8 ± 3.1ab | 6.5 ± 2.8abc

    PMID 26388707 · one of two readings recorded this

  • Repetitions completed, set 5

    n = 12

    Set 5 | 4.8 ± 3.0abcd | 5.4 ± 3.4abc | 5.4 ± 2.8abcd | 5.7 ± 3.1abcd

    PMID 26388707 · one of two readings recorded this

  • Repetitions completed, set 6

    n = 12

    Set 6 | 4.0 ± 2.7abcd | 4.1 ± 2.5abcde | 4.9 ± 3.0abcd | 5.3 ± 3.4abcd

    PMID 26388707 · one of two readings recorded this

  • Repetitions completed, sets 1 - 3

    n = 12

    Reps sets 1 – 3 | 24.7 ± 4.3 | 25.9 ± 3.6 | 27.1 ± 3.8 | 26.6 ± 3.7

    PMID 26388707 · one of two readings recorded this

  • Repetitions completed, sets 4 - 6

    n = 12

    Reps sets 4 – 6 | 14.8 ± 8.1 | 15.4 ± 8.7 | 17.1 ± 8.5# | 17.5 ± 9.2#

    PMID 26388707 · one of two readings recorded this

  • Repetitions in sets 4-6, treatment trend

    unclear, p = 0.06, n = 12

    In addition, a trend (P = 0.06) was observed where most of the differences shown between supplement conditions occurred between sets 4 and 6

    PMID 26388707 · one of two readings recorded this

  • RPE across successive sets, time effect

    increases, p = 0.0001, n = 12

    A significant time effect was observed between the 1st and 6th set of resistance exercise [P < 0.0001] where RPE values increased with each successive set

    PMID 26388707 · one of two readings recorded this

  • RPE correlated with repetitions completed per set

    decreases, p = 0.001, n = 12

    RPE obtained during each set was significantly [P < 0.001] negatively correlated with repetitions completed (r = −0.48 to −0.67)

    PMID 26388707 · one of two readings recorded this

  • Total repetitions (6 sets)

    increases, n = 12

    Total reps | 39.5 ± 12.1 | 41.3 ± 11.9 | 44.2 ± 11.7* | 44.1 ± 12.4*

    PMID 26388707 · one of two readings recorded this

  • total repetitions and volume load over 6 sets of back squat at 80% 1RM (up to 10 reps per set, 2 min rest); also mean power, peak power, RPE (CR10), blood lactate and body mass across conditions

    increases

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    Supplements SCF and S produced significantly greater numbers of repetitions performed than CT and P.

    PMID 26388707 · one of two readings recorded this

  • total repetitions and volume load over 6 sets of back squats at 80% of 1RM; also mean power and velocity (Tendo unit), RPE (CR10) and blood lactate

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    Supplements SCF and S produced significantly greater numbers of repetitions performed than CT and P.

    PMID 26388707 · one of two readings recorded this

  • Total repetitions, percent difference

    increases, n = 12

    SCF and S produced ~11.0 ± 8.0 % greater repetition numbers than the CT condition

    PMID 26388707 · one of two readings recorded this

  • Total repetitions, percent difference

    increases, n = 12

    and ~6.0 ± 7.0 % greater repetition numbers than the P treatment

    PMID 26388707 · one of two readings recorded this

  • Total repetitions, treatment main effect

    increases, p = 0.05, n = 12

    However, significant differences were observed [P = 0.05] between treatments when total repetitions were analyzed

    PMID 26388707 · one of two readings recorded this

  • Volume load per protocol, treatment main effect

    increases, p = 0.03, n = 12

    A significant difference was observed [P = 0.03] between treatments

    PMID 26388707 · one of two readings recorded this

  • Volume load per protocol

    increases, n = 12

    Supplements SCF (4,609.1 ± 1,175.2 kg) and S (4,623.0 ± 1,117.5 kg) produced a significantly greater volume load per protocol than CT (4,128.0 ± 1,258.1 kg) and P (4,321.6 ± 1,136 kg)

    PMID 26388707 · one of two readings recorded this

  • Carbohydrate oxidation rate at low-to-moderate exercise intensities

    decreases, n = 18

    The acute ingestion of p-synephrine increased the fat oxidation rate while it reduced the carbohydrate oxidation rate when exercising at low-to-moderate exercise intensities

    PMID 27038225 · one of two readings recorded this

  • carbohydrate oxidation rate during incremental cycling, indirect calorimetry

    decreases, n = 18

    Not recorded as a finding: no carbohydrate oxidation outcome node

    The acute ingestion of p-synephrine increased the fat oxidation rate while it reduced the carbohydrate oxidation rate when exercising at low-to-moderate exercise intensities.

    PMID 27038225 · one of two readings recorded this

  • Energy consumption at rest

    no effect, p = 0.69, n = 18

    did not change energy consumption (1.6 ± 0.3 vs. 1.6 ± 0.3 kcal min(-1) ; P = 0.69)

    PMID 27038225 · one of two readings recorded this

  • Energy expenditure during incremental exercise

    no effect, n = 18

    the intake of p-synephrine moved the fat oxidation-exercise intensity curve upwards during the incremental exercise (P < 0.05) without affecting energy expenditure

    PMID 27038225 · one of two readings recorded this

  • Exercise intensity at which maximal fat oxidation was achieved

    no effect, p = 0.51, n = 18

    it did not affect the intensity at which maximal fat oxidation was achieved (55.8 ± 7.7 vs. 56.7 ± 8.2% VO2peak ; P = 0.51)

    PMID 27038225 · one of two readings recorded this

  • fat oxidation during incremental exercise, expressed as the fat oxidation-exercise intensity curve

    increases, curve moved upwards, P < 0.05

    Not recorded as a finding: fat-oxidation-rate needs a rate at a stated intensity or a bout total; the finding is a curve shift across intensities with no per-intensity rate or total in the sentence

    However, the intake of p-synephrine moved the fat oxidation-exercise intensity curve upwards during the incremental exercise (P < 0.05) without affecting energy expenditure.

    PMID 27038225 · one of two readings recorded this

  • Fat oxidation-exercise intensity curve during incremental exercise

    increases, p = 0.05, n = 18

    the intake of p-synephrine moved the fat oxidation-exercise intensity curve upwards during the incremental exercise (P < 0.05) without affecting energy expenditure

    PMID 27038225 · one of two readings recorded this

  • Fat oxidation rate at low-to-moderate exercise intensities

    increases, n = 18

    The acute ingestion of p-synephrine increased the fat oxidation rate while it reduced the carbohydrate oxidation rate when exercising at low-to-moderate exercise intensities

    PMID 27038225 · one of two readings recorded this

  • Fat oxidation rate at rest

    no effect, p = 0.15, n = 18

    or fat oxidation rate at rest (0.08 ± 0.02 vs. 0.10 ± 0.04 g min(-1) ; P = 0.15)

    PMID 27038225 · one of two readings recorded this

  • maximal fat oxidation rate during cycle ergometer ramp exercise, indirect calorimetry

    increases, 0.29 vs 0.40 g/min, p = 0.01, n = 18

    Not recorded as a finding: this platform holds no node for the endpoint

    Moreover, p-synephrine increased maximal fat oxidation rate (0.29 ± 0.15 vs. 0.40 ± 0.18 g min(-1) ; P = 0.01) during exercise although it did not affect the intensity at which maximal fat oxidation was achieved (55.8 ± 7.7 vs. 56.7 ± 8.2% VO2peak ; P = 0.51).

    PMID 27038225 · one of two readings recorded this

  • Maximal fat oxidation rate during exercise

    increases, p = 0.01, n = 18

    Moreover, p-synephrine increased maximal fat oxidation rate (0.29 ± 0.15 vs. 0.40 ± 0.18 g min(-1) ; P = 0.01) during exercise

    PMID 27038225 · one of two readings recorded this

  • maximal fat oxidation rate (g/min) during a cycle ergometer ramp test, indirect calorimetry; fat oxidation and energy expenditure at rest

    increases, 0.29 vs 0.40 g/min, P = 0.01, p = 0.01, n = 18

    Not recorded as a finding: this platform holds no node for the endpoint

    Moreover, p-synephrine increased maximal fat oxidation rate (0.29 ± 0.15 vs. 0.40 ± 0.18 g min(-1) ; P = 0.01) during exercise although it did not affect the intensity at which maximal fat oxidation was achieved (55.8 ± 7.7 vs. 56.7 ± 8.2% VO2peak ; P = 0.51).

    PMID 27038225 · one of two readings recorded this

  • resting energy consumption, indirect calorimetry, kcal/min

    no effect, 1.6 ± 0.3 vs. 1.6 ± 0.3 kcal/min, p = 0.69, n = 18

    Not recorded as a finding: resting-energy-expenditure node requires an overnight fast and no prior exercise, and the abstract states neither; the sentence's 'at rest' also attaches grammatically to fat oxidation

    In comparison with the placebo, the ingestion of p-synephrine did not change energy consumption (1.6 ± 0.3 vs. 1.6 ± 0.3 kcal min(-1) ; P = 0.69) or fat oxidation rate at rest (0.08 ± 0.02 vs. 0.10 ± 0.04 g min(-1) ; P = 0.15).

    PMID 27038225 · one of two readings recorded this

  • resting energy expenditure ('energy consumption'), indirect calorimetry, kcal/min

    no effect, 1.6 vs 1.6 kcal/min, p = 0.69

    Not recorded as a finding: resting-energy-expenditure requires lying at rest after an overnight fast without prior exercise, converted to per-day; the abstract states none of those conditions, so the node's measurement cannot be confirmed

    In comparison with the placebo, the ingestion of p-synephrine did not change energy consumption (1.6 ± 0.3 vs. 1.6 ± 0.3 kcal min(-1) ; P = 0.69) or fat oxidation rate at rest (0.08 ± 0.02 vs. 0.10 ± 0.04 g min(-1) ; P = 0.15).

    PMID 27038225 · one of two readings recorded this

  • carbohydrate oxidation during 1 h of cycling

    decreases, p = 0.01, n = 14

    99.5 ± 30.4 vs. 85.0 ± 28.4 g, P < 0.01

    PMID 31691018 · one of two readings recorded this

  • carbohydrate oxidation summed over 1 h of cycling at Fatmax, indirect calorimetry

    decreases, 99.5 ± 30.4 vs. 85.0 ± 28.4 g, n = 14

    Not recorded as a finding: no carbohydrate oxidation outcome node

    However, p-synephrine increased whole-body fat oxidation (33.6 ± 10.4 vs. 37.3 ± 9.8 g, P < 0.01) while also reducing carbohydrate oxidation (99.5 ± 30.4 vs. 85.0 ± 28.4 g, P < 0.01).

    PMID 31691018 · one of two readings recorded this

  • energy expenditure during 1 h of cycling at Fatmax, indirect calorimetry, kcal

    no effect, 698 ± 129 vs. 686 ± 123 kcal, p = 0.08, n = 14

    Not recorded as a finding: exercising energy expenditure; resting-energy-expenditure node requires a rest measurement after an overnight fast

    In comparison to the placebo, energy expenditure during 1 h of cycling remained unchanged with p-synephrine (698 ± 129 vs. 686 ± 123 kcal, P = 0.08).

    PMID 31691018 · both readings recorded this

  • energy expenditure during 1 h of cycling

    no effect, p = 0.08, n = 14

    698 ± 129 vs. 686 ± 123 kcal, P = 0.08

    PMID 31691018 · one of two readings recorded this

  • whole-body fat oxidation and carbohydrate oxidation over 1 h of cycling at Fatmax, indirect calorimetry

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    However, p-synephrine increased whole-body fat oxidation (33.6 ± 10.4 vs. 37.3 ± 9.8 g, P < 0.01) while also reducing carbohydrate oxidation (99.5 ± 30.4 vs. 85.0 ± 28.4 g, P < 0.01).

    PMID 31691018 · one of two readings recorded this

  • whole-body fat oxidation during 1 h of cycling

    increases, p = 0.01, n = 14

    33.6 ± 10.4 vs. 37.3 ± 9.8 g, P < 0.01

    PMID 31691018 · one of two readings recorded this

  • whole-body fat oxidation (g) over 1 h of cycling at Fatmax, indirect calorimetry; also carbohydrate oxidation and energy expenditure

    increases, 33.6 vs 37.3 g, P < 0.01, n = 14

    Not recorded as a finding: this platform holds no node for the endpoint

    However, p-synephrine increased whole-body fat oxidation (33.6 ± 10.4 vs. 37.3 ± 9.8 g, P < 0.01) while also reducing carbohydrate oxidation (99.5 ± 30.4 vs. 85.0 ± 28.4 g, P < 0.01).

    PMID 31691018 · one of two readings recorded this

  • Anthropometric variables

    no effect

    Statistically significant changes in anthropometric variables, scores of the physical health, mental health, and total score of the SF-12 questionnaire were not found in the study groups

    PMID 32438719 · one of two readings recorded this

  • Blood cell count, liver enzymes, blood urea nitrogen and serum creatinine (safety)

    no effect

    Neither adverse events nor changes in cell blood count, liver enzymes, and serum levels of blood urea nitrogen and creatinine were observed

    PMID 32438719 · one of two readings recorded this

  • Diastolic blood pressure

    decreases, p = 0.045

    Between-group differences were significant for diastolic blood pressure (p = 0.045)

    PMID 32438719 · one of two readings recorded this

  • Diastolic blood pressure

    decreases, n = 51

    Both systolic and diastolic blood pressure decreased significantly in the active product group, whereas changes were not significant among participants treated with placebo

    PMID 32438719 · one of two readings recorded this

  • Diastolic blood pressure

    no effect, n = 45

    Both systolic and diastolic blood pressure decreased significantly in the active product group, whereas changes were not significant among participants treated with placebo

    PMID 32438719 · one of two readings recorded this

  • Flow-mediated vasodilation (FMD)

    increases, p = 0.039

    Between-group differences in FMD were statistically significant (p = 0.039)

    PMID 32438719 · one of two readings recorded this

  • Flow-mediated vasodilation (FMD)

    increases, p = 0.001, n = 51

    The comparison of baseline (6.73 ± 5.27%) and final values (9.77 ± 5.56%) showed statistically significant differences (p < 0.001) in the active product group, whereas differences were not significant in the placebo group

    PMID 32438719 · one of two readings recorded this

  • Flow-mediated vasodilation (FMD)

    no effect, n = 45

    The comparison of baseline (6.73 ± 5.27%) and final values (9.77 ± 5.56%) showed statistically significant differences (p < 0.001) in the active product group, whereas differences were not significant in the placebo group

    PMID 32438719 · one of two readings recorded this

  • Interleukin-6 (IL-6)

    decreases, p = 0.001

    Between-group differences in serum levels of IL-6 during the study were statistically significant (p < 0.001)

    PMID 32438719 · one of two readings recorded this

  • Interleukin-6 (IL-6)

    decreases, p = 0.001, n = 51

    serum levels of IL-6 decreased from 1.49 ± 0.96 pg/mL at baseline to 0.91 ± 0.56 pg/mL after eight weeks of treatment with the active product (p < 0.001)

    PMID 32438719 · one of two readings recorded this

  • Interleukin-6 (IL-6)

    no effect, n = 45

    whereas changes in the placebo group were not significant

    PMID 32438719 · one of two readings recorded this

  • LDL-C

    unclear

    with statistically significant differences for within-group comparisons in subjects assigned to the active product group, as well as between group-differences versus placebo

    PMID 32438719 · one of two readings recorded this

  • LDL-C

    unclear, n = 51

    there was a significant improvement in serum levels of total cholesterol, LDL-C, and oxidized-LDL (ox-LDL), with statistically significant differences for within-group comparisons in subjects assigned to the active product group

    PMID 32438719 · one of two readings recorded this

  • Level of physical activity

    no effect

    Significant changes in the level of physical activity were not recorded

    PMID 32438719 · one of two readings recorded this

  • Oxidized LDL

    unclear

    with statistically significant differences for within-group comparisons in subjects assigned to the active product group, as well as between group-differences versus placebo

    PMID 32438719 · one of two readings recorded this

  • Oxidized LDL

    unclear, n = 51

    there was a significant improvement in serum levels of total cholesterol, LDL-C, and oxidized-LDL (ox-LDL), with statistically significant differences for within-group comparisons in subjects assigned to the active product group

    PMID 32438719 · one of two readings recorded this

  • Protein carbonyl

    decreases, p = 0.012

    Between-group comparisons of these variables showed statistically significant differences (p = 0.003 and p = 0.012, respectively)

    PMID 32438719 · one of two readings recorded this

  • Protein carbonyl

    decreases, n = 51

    protein carbonyl decreased significantly in the active product treatment group only

    PMID 32438719 · one of two readings recorded this

  • Reduced/oxidized glutathione ratio (GSH/GSSH)

    increases, p = 0.003

    Between-group comparisons of these variables showed statistically significant differences (p = 0.003 and p = 0.012, respectively)

    PMID 32438719 · one of two readings recorded this

  • Reduced/oxidized glutathione ratio (GSH/GSSH)

    increases, n = 51

    the GHS/GSSH ratio increased significantly in the active product treatment product only

    PMID 32438719 · one of two readings recorded this

  • SF-12 physical health, mental health and total scores

    no effect

    Statistically significant changes in anthropometric variables, scores of the physical health, mental health, and total score of the SF-12 questionnaire were not found in the study groups

    PMID 32438719 · one of two readings recorded this

  • Systolic blood pressure

    decreases, n = 51

    Both systolic and diastolic blood pressure decreased significantly in the active product group, whereas changes were not significant among participants treated with placebo

    PMID 32438719 · one of two readings recorded this

  • Systolic blood pressure

    no effect, n = 45

    Both systolic and diastolic blood pressure decreased significantly in the active product group, whereas changes were not significant among participants treated with placebo

    PMID 32438719 · one of two readings recorded this

  • Total cholesterol

    unclear

    with statistically significant differences for within-group comparisons in subjects assigned to the active product group, as well as between group-differences versus placebo

    PMID 32438719 · one of two readings recorded this

  • Total cholesterol

    unclear, n = 51

    there was a significant improvement in serum levels of total cholesterol, LDL-C, and oxidized-LDL (ox-LDL), with statistically significant differences for within-group comparisons in subjects assigned to the active product group

    PMID 32438719 · one of two readings recorded this

  • von Willebrand factor

    no effect

    No significant differences were found in levels of the von Willebrand factor for any other group of the study

    PMID 32438719 · one of two readings recorded this

  • diastolic blood pressure

    53.30 ± 10.13, 134.82 ± 11.75 mm Hg, 84.49 ± 6.99 mm Hg, 17.87 ± 1.73 times/min, and 76.48 ± 12.55 beats/min at baseline

    PMID 32572778 · one of two readings recorded this

  • diastolic blood pressure

    decreases, p = 0.05

    significantly decreased to 42.37 ± 10.15, 124.49 ± 10.48 mm Hg, 79.23 ± 6.62 mm Hg, 14.54 ± 1.43 times/min, and 70.03 ± 13.66 beats/min respectively 20 min after intervention (all P<0.05)

    PMID 32572778 · one of two readings recorded this

  • pulse rate

    53.30 ± 10.13, 134.82 ± 11.75 mm Hg, 84.49 ± 6.99 mm Hg, 17.87 ± 1.73 times/min, and 76.48 ± 12.55 beats/min at baseline

    PMID 32572778 · one of two readings recorded this

  • pulse rate

    decreases, p = 0.05

    significantly decreased to 42.37 ± 10.15, 124.49 ± 10.48 mm Hg, 79.23 ± 6.62 mm Hg, 14.54 ± 1.43 times/min, and 70.03 ± 13.66 beats/min respectively 20 min after intervention (all P<0.05)

    PMID 32572778 · one of two readings recorded this

  • respiratory rate

    53.30 ± 10.13, 134.82 ± 11.75 mm Hg, 84.49 ± 6.99 mm Hg, 17.87 ± 1.73 times/min, and 76.48 ± 12.55 beats/min at baseline

    PMID 32572778 · one of two readings recorded this

  • respiratory rate

    decreases, p = 0.05

    significantly decreased to 42.37 ± 10.15, 124.49 ± 10.48 mm Hg, 79.23 ± 6.62 mm Hg, 14.54 ± 1.43 times/min, and 70.03 ± 13.66 beats/min respectively 20 min after intervention (all P<0.05)

    PMID 32572778 · one of two readings recorded this

  • STAI score and vital signs

    no effect, p = 0.05

    in the control group, neither anxiety scores nor vital signs changed significantly (P>0.05)

    PMID 32572778 · one of two readings recorded this

  • STAI score

    53.30 ± 10.13, 134.82 ± 11.75 mm Hg, 84.49 ± 6.99 mm Hg, 17.87 ± 1.73 times/min, and 76.48 ± 12.55 beats/min at baseline

    PMID 32572778 · one of two readings recorded this

  • STAI score

    decreases, p = 0.05

    significantly decreased to 42.37 ± 10.15, 124.49 ± 10.48 mm Hg, 79.23 ± 6.62 mm Hg, 14.54 ± 1.43 times/min, and 70.03 ± 13.66 beats/min respectively 20 min after intervention (all P<0.05)

    PMID 32572778 · one of two readings recorded this

  • systolic blood pressure

    53.30 ± 10.13, 134.82 ± 11.75 mm Hg, 84.49 ± 6.99 mm Hg, 17.87 ± 1.73 times/min, and 76.48 ± 12.55 beats/min at baseline

    PMID 32572778 · one of two readings recorded this

  • systolic blood pressure

    decreases, p = 0.05

    significantly decreased to 42.37 ± 10.15, 124.49 ± 10.48 mm Hg, 79.23 ± 6.62 mm Hg, 14.54 ± 1.43 times/min, and 70.03 ± 13.66 beats/min respectively 20 min after intervention (all P<0.05)

    PMID 32572778 · one of two readings recorded this

  • energy expenditure during exercise

    no effect, p = 0.4

    The ingestion of p-synephrine had no significant effects on energy expenditure (F = 0.71, P = 0.40)

    PMID 32859142 · one of two readings recorded this

  • energy expenditure during incremental exercise, stoichiometric equations

    no effect, F = 0.71, p = 0.4

    Not recorded as a finding: no node: resting-energy-expenditure requires measurement at rest, and this is exercising expenditure

    The ingestion of p-synephrine had no significant effects on energy expenditure (F = 0.71, P = 0.40) or heart rate (F = 0.66, P = 0.43) during exercise.

    PMID 32859142 · one of two readings recorded this

  • exercise intensity of maximal fat oxidation (Fatmax)

    no effect, p = 0.52

    Fatmax = 49; 48-53 vs 50; 47-51% Wmax, P = 0.52

    PMID 32859142 · one of two readings recorded this

  • fat oxidation rate and maximal fat oxidation (MFO, Fatmax) during incremental cycle ergometer test, breath-by-breath stoichiometric estimate; energy expenditure and heart rate during exercise

    no effect, maximal fat oxidation rate 0.91 vs 1.01 g/min, 95% CI 0.79-1.03 vs 0.91-1.11, p = 0.06

    Not recorded as a finding: this platform holds no node for the endpoint

    The ingestion of p-synephrine did not modify the maximal rate of fat oxidation during the ramp test (mean value; 95%CI = 0.91; 0.79-1.03 vs 1.01; 0.91-1.11 g/min, respectively, P = 0.06) nor the exercise intensity at which maximal fat oxidation was achieved (i.e. Fatmax = 49; 48-53 vs 50; 47-51% Wmax, P = 0.52).

    PMID 32859142 · one of two readings recorded this

  • heart rate during exercise

    no effect, p = 0.43

    heart rate (F = 0.66, P = 0.43) during exercise

    PMID 32859142 · one of two readings recorded this

  • maximal rate of fat oxidation during ramp test

    no effect, p = 0.06

    mean value; 95%CI = 0.91; 0.79-1.03 vs 1.01; 0.91-1.11 g/min, respectively, P = 0.06

    PMID 32859142 · one of two readings recorded this

  • maximal rate of fat oxidation (g/min) and Fatmax during an incremental maximal cycle ergometer test, breath-by-breath gas exchange

    no effect, maximal fat oxidation 0.91 vs 1.01 g/min, P = 0.06; Fatmax 49 vs 50% Wmax, P = 0.52, p = 0.06, n = 15

    Not recorded as a finding: this platform holds no node for the endpoint

    The ingestion of p-synephrine did not modify the maximal rate of fat oxidation during the ramp test (mean value; 95%CI = 0.91; 0.79-1.03 vs 1.01; 0.91-1.11 g/min, respectively, P = 0.06) nor the exercise intensity at which maximal fat oxidation was achieved (i.e. Fatmax = 49; 48-53 vs 50; 47-51% Wmax, P = 0.52).

    PMID 32859142 · one of two readings recorded this

  • rate of fat oxidation at the loads tested

    increases

    the rate of fat oxidation was higher with p-synephrine in the following loads

    PMID 32859142 · one of two readings recorded this

  • rate of fat oxidation, main effect

    increases, p = 0.04

    there was a main effect of p-synephrine to increase the rate of fat oxidation over the placebo (F = 5.1, P = 0.04)

    PMID 32859142 · one of two readings recorded this

  • quality of life

    increases

    There was a significant difference between the mean score of quality of life in the Lavender essential oil group and Citrus Aurantium essential oil group with the control group after intervention

    PMID 32889038 · one of two readings recorded this

  • quality of life

    increases

    There was a significant difference between the mean score of quality of life in the Lavender essential oil group and Citrus Aurantium essential oil group with the control group after intervention

    PMID 32889038 · one of two readings recorded this

  • quality of life

    no effect

    However, there was no significant difference between the mean score of quality of life in the Lavender essential oil group and Citrus Aurantium essential oil group after the intervention

    PMID 32889038 · one of two readings recorded this

  • pain score, all groups over the study

    decreases, p = 0.001

    Pain scores of all groups decreased during the study (P < 0.001)

    PMID 33516726 · one of two readings recorded this

  • pain score, lavender versus placebo

    decreases

    The mean pain of the lavender group was significantly lower than that of the placebo group at three hours after the intervention

    PMID 33516726 · one of two readings recorded this

  • pain score

    decreases

    The mean pain score of the C. aurantium group was 45.48 before the intervention and was reduced to 32.34 at three hours after the intervention

    PMID 33516726 · one of two readings recorded this

  • pain score

    no effect

    The mean pain score of the lavender group was 40.01 before the aromatherapy intervention and fell to 39.40, 30.60 and 23.68 immediately after the intervention, and at hour one and three post-intervention, respectively

    PMID 33516726 · one of two readings recorded this

  • pain score

    decreases

    The mean pain score of the lavender group was 40.01 before the aromatherapy intervention and fell to 39.40, 30.60 and 23.68 immediately after the intervention, and at hour one and three post-intervention, respectively

    PMID 33516726 · one of two readings recorded this

  • pain score

    decreases

    The mean pain score of the lavender group was 40.01 before the aromatherapy intervention and fell to 39.40, 30.60 and 23.68 immediately after the intervention, and at hour one and three post-intervention, respectively

    PMID 33516726 · one of two readings recorded this

  • pain score

    decreases

    The mean pain of the placebo group decreased from 42.80 before the intervention to 35.20 at three hours after the intervention

    PMID 33516726 · one of two readings recorded this

  • anxiety severity (STAI) in women

    increases, p = 0.05

    In addition, the severity of anxiety in women in the control group increased after placebo intervention (p<0.05)

    PMID 33984876 · one of two readings recorded this

  • relatively severe anxiety in women, spring orange group

    decreases

    In women, relatively severe anxiety was not observed after the intervention with lavender, but in the spring orange group, only in 6.7% of people, relatively severe anxiety and traits were observed

    PMID 33984876 · one of two readings recorded this

  • Best-corrected visual acuity (BCVA)

    no effect, p = 0.502, n = 30

    BCVA | 100.77 ± 9.02 | 103.08 ± 6.01 | 0.185 | 103.00 ± 7.83 | 102.33 ± 7.51 | 0.502

    PMID 34647961 · one of two readings recorded this

  • Best-corrected visual acuity (BCVA)

    no effect, p = 0.185, n = 26

    BCVA | 100.77 ± 9.02 | 103.08 ± 6.01 | 0.185 | 103.00 ± 7.83 | 102.33 ± 7.51 | 0.502

    PMID 34647961 · one of two readings recorded this

  • Cone sensitivity

    no effect, p = 0.996, n = 30

    Cone sensitivity (%) | 5.86 ± 2.97 | 5.37 ± 3.18 | 0.159 | 4.84 ± 1.88 | 4.84 ± 1.85 | 0.996

    PMID 34647961 · one of two readings recorded this

  • Cone sensitivity

    no effect, p = 0.159, n = 26

    Cone sensitivity (%) | 5.86 ± 2.97 | 5.37 ± 3.18 | 0.159 | 4.84 ± 1.88 | 4.84 ± 1.85 | 0.996

    PMID 34647961 · one of two readings recorded this

  • Effect of floaters on daily life, mean score

    decreases, p = 0.002, n = 30

    Mean score | 1.08 ± 0.85 | 1.00 ± 1.06 | 0.678 | 1.37 ± 1.27 | 0.73 ± 0.94 | 0.002 *

    PMID 34647961 · one of two readings recorded this

  • Effect of floaters on daily life, mean score

    no effect, p = 0.678, n = 26

    Mean score | 1.08 ± 0.85 | 1.00 ± 1.06 | 0.678 | 1.37 ± 1.27 | 0.73 ± 0.94 | 0.002 *

    PMID 34647961 · one of two readings recorded this

  • Letter contrast sensitivity, 1.5 cpd

    no effect, p = 0.749, n = 30

    1.5 cpd | 1.90 ± 0.18 | 1.93 ± 0.14 | 0.354 | 1.96 ± 0.20 | 1.95 ± 0.19 | 0.749

    PMID 34647961 · one of two readings recorded this

  • Letter contrast sensitivity, 1.5 cpd

    no effect, p = 0.354, n = 26

    1.5 cpd | 1.90 ± 0.18 | 1.93 ± 0.14 | 0.354 | 1.96 ± 0.20 | 1.95 ± 0.19 | 0.749

    PMID 34647961 · one of two readings recorded this

  • Letter contrast sensitivity, 12 cpd

    no effect, p = 0.51, n = 30

    12 cpd | 1.27 ± 0.39 | 1.39 ± 0.29 | 0.104 | 1.38 ± 0.36 | 1.42 ± 0.40 | 0.510

    PMID 34647961 · one of two readings recorded this

  • Letter contrast sensitivity, 12 cpd

    no effect, p = 0.104, n = 26

    12 cpd | 1.27 ± 0.39 | 1.39 ± 0.29 | 0.104 | 1.38 ± 0.36 | 1.42 ± 0.40 | 0.510

    PMID 34647961 · one of two readings recorded this

  • Letter contrast sensitivity, 18.95 cpd

    no effect, p = 0.281, n = 30

    18.95 cpd | 0.94 ± 0.49 | 1.02 ± 0.38 | 0.276 | 1.07 ± 0.33 | 1.12 ± 0.33 | 0.281

    PMID 34647961 · one of two readings recorded this

  • Letter contrast sensitivity, 18.95 cpd

    no effect, p = 0.276, n = 26

    18.95 cpd | 0.94 ± 0.49 | 1.02 ± 0.38 | 0.276 | 1.07 ± 0.33 | 1.12 ± 0.33 | 0.281

    PMID 34647961 · one of two readings recorded this

  • Letter contrast sensitivity, 3 cpd

    no effect, p = 0.109, n = 30

    3 cpd | 1.87 ± 0.18 | 1.89 ± 0.17 | 0.465 | 1.94 ± 0.19 | 1.98 ± 0.22 | 0.109

    PMID 34647961 · one of two readings recorded this

  • Letter contrast sensitivity, 3 cpd

    no effect, p = 0.465, n = 26

    3 cpd | 1.87 ± 0.18 | 1.89 ± 0.17 | 0.465 | 1.94 ± 0.19 | 1.98 ± 0.22 | 0.109

    PMID 34647961 · one of two readings recorded this

The whole record — 387 rows